HROW
Harrow
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
Consensus Rating "Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HROW
Harrow, Inc.
An eyecare pharmaceutical company that developing innovative ophthalmic prescription therapies
1A Burton Hills Blvd., Suite 200, Nashville, Tennessee 37215
--
Harrow, Inc., formed in Delaware in January 2006 as Bywater Resources Corporation, is primarily involved in mineral development activities. On September 11, 2007, it was renamed Transdel Pharmaceuticals, and on December 13, 2018, it was renamed Harrow Health. The company is an ophthalmology-focused pharmaceutical company specializing in the development, production and sale of innovative medicines that provide unique competitive advantages and meet unmet needs in the market. They are committed to fulfilling the company's mission to deliver high-quality new medicines to physicians and patients at affordable prices.
Earnings Call
Q1/2025
Estimate EPS0.01
Actual EPS-0.38
Estimate Revenue57.00M
Actual Revenue47.83M
Harrow Health's Q1 2025: Key Contradictions on Market Share, Medicare Coverage, and Pricing Strategies
May 20,2025 01:53
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
HROW has released its 2025 Q1 earnings. EPS was reported at -0.38, versus the expected 0.01, missing expectations. The chart below visualizes how HROW has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HROW has released its 2025 Q1 earnings report, with revenue of 47.83M, reflecting a YoY change of 38.29%, and net profit of -17.78M, showing a YoY change of -31.07%. The Sankey diagram below clearly presents HROW's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
